Aurobindo Pharma Share Price in Focus; Receives US FTC Nod for Lannett Acquisition

Aurobindo Pharma Limited has received regulatory approval from the US Federal Trade Commission (FTC) for its proposed acquisition of Lannett Company LLC through its wholly owned subsidiary, Aurobindo Pharma USA Inc. 

The development marks a key milestone in the transaction process and moves the acquisition closer to completion.  

FTC Approves Lannett Acquisition 

The company informed stock exchanges that the necessary approval from the US Federal Trade Commission has been obtained for the acquisition of Lannett Company LLC. 

The approval removes a major regulatory hurdle for the transaction announced earlier by the company.  

Acquisition Announced Last Year 

Aurobindo Pharma had previously disclosed that Aurobindo Pharma USA Inc. entered into a definitive agreement with LANNETT SELLER HOLDCO, INC. to acquire 100% membership interest in Lannett Company LLC. The acquisition is being undertaken through the company's US subsidiary.  

Following the receipt of FTC approval, Aurobindo Pharma stated that it expects the transaction to be completed before the end of the current month.  

Read More: Power Mech Projects Share Price in Focus; Secures Order Worth ₹1,008.90 Crore from JSW Thermal Energy! 

Aurobindo Pharma Share Price Performance 

As of 22 June 2026, at 9:30 AM, Aurobindo Pharma share price was trading at ₹1,494.90 per share, reflecting a decline of 0.19% from the previous trading session. 

Conclusion 

Aurobindo Pharma has secured FTC approval for its proposed acquisition of Lannett Company LLC through its US subsidiary. With the regulatory clearance in place, the company expects the transaction to be completed before the end of the month, marking an important step in its US market expansion strategy.  

Want to read stock market updates in Hindi? Angel One News gives comprehensive share market news in Hindi. 

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.